Novavax's (NVAX) COVID-19 vaccine has been approved for use by the US Food and Drug Administration but limited to only those over 65 years old and to those over 12 years old with underlying medical conditions, news outlets reported Saturday, citing company officials.
Reuters cited Novavax's Chief Corporate Affairs and Advocacy Officer Silvia Taylor as saying the approval for the drug, sold under the name Nuvaxovid, came late Friday night.
Novavax did not immediately reply to MT Newswires' request for comment.
Novavax Chief Executive John Jacobs described the approval as a "significant milestone" in a statement cited by Reuters.
Shares of the US biotech firm were up more than 16% in recent premarket activity Monday.
Price: 7.86, Change: +1.13, Percent Change: +16.79
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。